Scott S D
University of Iowa College of Pharmacy, Division of Clinical and Administrative Pharmacy, Iowa City, USA.
Cancer Pract. 1998 May-Jun;6(3):195-7. doi: 10.1046/j.1523-5394.1998.006003195.x.
Rituximab is an effective single agent available for short-course outpatient treatment in low-grade NHL, particularly with follicular histology (IWF B-D), that offers a relatively nontoxic alternative to chemotherapy regimens currently available. Early indications are that retreatment is effective with similar levels of predictable adverse events to the initial course of therapy. Further development is awaited of regimens that combine rituximab with chemotherapeutic agents to enhance treatment efficacy without overlapping side effects in low-grade NHL as well as use in other CD20+ malignancies.
利妥昔单抗是一种有效的单一药物，可用于低度非霍奇金淋巴瘤（NHL）的短程门诊治疗，特别是滤泡性组织学类型（国际工作分类法B-D级），它为目前可用的化疗方案提供了一种相对无毒的替代方案。早期迹象表明，再次治疗是有效的，且可预测的不良事件水平与初始治疗疗程相似。人们期待进一步研发将利妥昔单抗与化疗药物联合使用的方案，以提高低度NHL的治疗效果，同时避免副作用重叠，以及期待其在其他CD20+恶性肿瘤中的应用。
